A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer

por Tuli, R., Shiao, S.L., Nissen, N., Tighiouart, M., Kim, S., Osipov, A., Bryant, M., Ristow, L., Placencio-Hickok, V.R., Hoffman, D., Rokhsar, S., Scher, K., Klempner, S.J., Noe, P., Davis, M.J., Wachsman, A., Lo, S., Jamil, L., Sandler, H., Piantadosi, S., Hendifar, A.
Publicado 2019